An Overview of Pharmacotherapy Options for Alcohol Use Disorder
Clinical trials have found a number of pharmacotherapy options to be effective, but despite the need and the proven benefits, the use of pharmacotherapy remains low.
Jasmine Carpenter is a Mental Health Clinical Pharmacy Specialist; Danielle LaPrad and Yewande Dayo are Pharmacy Practice Residents; and Shannon DeGrote is a Clinical Pharmacy Specialist, all at the Washington DC VA Medical Center. Kasraie Williamson is a Pharmacy Resident at Memorial Regional Hospital in Hollywood, Florida. Correspondence: Jasmine Carpenter (jasmine.carpenter@va.gov)
Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
Conclusion
There is a major disparity in the prevalence of AUD between the general population and the military and veteran populations. Many clinical trials have found a number of pharmacotherapy options to be effective for the treatment of AUD. Despite the need and the proven benefits, the utilization of AUD pharmacotherapy still remains low in both the general and veteran populations. Increasing provider education and addressing other potential barriers for the use of pharmacotherapy for AUD can have a positive impact on prescribing patterns, which can ultimately improve alcohol consumption outcomes in patients with a diagnosis of AUD.